IN this issue of the Journal, Herzig and Alavi and their respective associates provide the most definitive evidence published to date that transfusion of neutrophils is a beneficial adjunct in the treatment of infected, neutropenic patients. As the authors state, previous studies have provided convincing data in laboratory animals and suggestive data in man on this benefit. However, I agree with the authors that previous reports of human studies have suffered from flaws in experimental design. I doubt if anyone knowledgeable about neutrophils and their role in combating infections has ever doubted that an adequate number of adequately functional, . . .